Abstract

(1) Background: The Genetic Counseling Satisfaction Scale (GCSS) is a widely used tool to evaluate patient satisfaction. To our knowledge, a validated French-language version of this tool is not yet available. This article reports on the cross-cultural adaptation and validation of a French version of the Genetic Counseling Satisfaction Scale (GCSS) to evaluate genetic counseling services for patient consultation in hereditary breast and ovarian cancer (HBOC). (2) Methods: The scale was culturally adapted following guidelines from Beaton et al. (2000). Cognitive interviews were conducted to ensure items were understood according to the intended meaning. The internal consistency, floor and ceiling effects, and testing of group differences were assessed using a sample of 172 patients who attended a pretest group genetic counseling session. (3) Results: Participants understood all items according to the intended meaning. The internal consistency was high for the total scale (0.90) and for the corrected item-to-total correlations (varying between 0.62 and 0.78). No floor or ceiling effects were observed. Group difference analyses generally followed expectations. (4) Conclusion: This process generated a French version of the GCSS that is clearly understood by patients, and has psychometric properties adequately in line those reported for its original English version.

Highlights

  • Hereditary breast-ovarian cancer (HBOC) is among the most common hereditary cancer syndromes

  • This paper presents the cross-cultural adaptation and validation of a French version of the Genetic Counseling Satisfaction Scale (GCSS) to evaluate genetic counseling services for patients consulting for hereditary breast and ovarian cancer (HBOC)

  • All participants had already completed the French version of the GCSS a few days after their counseling session

Read more

Summary

Introduction

Hereditary breast-ovarian cancer (HBOC) is among the most common hereditary cancer syndromes. Up to 10% of breast cancer cases are estimated to be inherited genetic variants in highly penetrant susceptibility genes [1,2]. Carriers of pathogenic variants in the BRCA1 or BRCA2 genes have a 5- to 20-fold increased risk of developing breast or ovarian cancer [3,4]. This translates to an estimated cumulative lifetime risk of developing breast cancer at 72% for BRCA1 and 69% for BRCA2 pathogenic variant carriers [5]. The systematic use of validated satisfaction scales, such as the Genetic Counseling Satisfaction Scale (GCSS), is a concrete way to monitor the attainment of this outcome [8]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call